COMPARISION AND ASSESSMENT OF PROBIOTICS BY ORAL ROUTE AND LOCAL APPLICATION AS AN ADDITION TO STANDARD THERAPY IN TREATMENT OF FEMALE GENITAL INFECTIONS.

"COMPARATIVE ASSESSMENT OF ORAL AND LOCAL PROBIOTICS AS AN ADJUNCT TO STANDARD THERAPY FOR VULVO VAGINITIS"

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/12/004182

Enrollment

Registered

2013-12-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATIENTS DIAGNOSED WITH VULVO VAGINITIS

Interventions

Intervention1: GROUP B ( ORAL PROBIOTIC GROUP): 30 PATIENTS WITH VULVO VAGINITIS PUT ON STANDARD THERAPY AND ORAL PROBIOTICS. (a kit of azithromycin 1g 1tablet, secnidazole 1g 2 tablets, fluconazo

Eligibility

Inclusion criteria

Inclusion criteria: • Females (age 18-60 years). • Clinical Diagnosis of vulvo vaginitis.

Exclusion criteria

Exclusion criteria: •Pregnancy, •HIV, on steroids therapy (immune compromised) •Hospitalized patients with poor general condition. •Major surgery, 3 months prior to Visit 1. •Significant co morbid diseases. •History of unexplained fever and sepsis. •History of any other genital pathology or neoplasia. •Hypersensitivity reactions to lactic acid derivatives.

Design outcomes

Primary

Measure	Time frame
CLINICAL IMPROVEMENTTimepoint: CLINICAL IMPROVEMENT AT 7 DAYS AFTER TREATMENT AND RECURRENCE RATE AT 30 DAYS.	—

Secondary

Measure	Time frame
SAFETY PROFILE OF DRUG AND BEST ROUTE OF ADMINISTRATION Timepoint: 0,7.30 days	—

Countries

India

Contacts

Public ContactDR PRINCY LOUIS PALATTY

FATHER MULLER MEDICAL COLLEGE, MANGALORE.

drprincylouispalatty@gmail.com9845104505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026